We have prepared a nanoformulation of anticancer drug and performed MTT and SRB assay of API, nanoformulation and placebo (nanoformulation without drug) at concentrations of 5-100 ug/ml. 

OD readings were observed at a range of 2-3 for all the concentrations for MTT assay. We thought that MTT is interfering with the formulation components and tried with SRB assay.

In SRB assay, we found OD of placebo was more than control

For nanoformulation OD readings were also more than control but less than placebo

Can anyone suggest the interpretation of results or share any protocol for the same

Regards,

Manikanta

Similar questions and discussions